Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
ARQTArcutis Biotherapeutics(ARQT) Newsfilter·2024-05-13 20:00

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation dataCrodafos™ CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair typesFindings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis WESTLAKE VILL ...